Merck & Co. Buys Into Mestag's Fibroblast Approach To Treat Inflammation

Deal Snapshot: The Cambridge, UK-based company could be in line for payments just shy of $2bn if its partnership with the US giant comes up trumps.

Susan Hill
Susan Hill • Source: Mestag

Who: Mestag/Merck & Co

What: The UK biotech has entered into a license and collaboration agreement with the US behemoth to identify targets for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immunological

More from Therapy Areas

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.